| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 13,800 | 13,900 | 17:49 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16:49 | XFRA ISIN CHANGE | 196 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenFR0010641449 Agrogeneration S.A. 20.11.2026 FR001401BA75 Agrogeneration S.A. 23.11.2026 Tausch 110:1US1280583022 Lisata... ► Artikel lesen | |
| 12.11. | Rallybio Corp - 8-K, Current Report | - | SEC Filings | ||
| AVENZO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.11. | Rallybio sets one-for-two reverse split ahead of planned merger with Avenzo | 1 | Seeking Alpha | ||
| 10.11. | Rallybio announces 1-for-2 reverse stock split effective Nov. 20 | 1 | Investing.com | ||
| 10.11. | Rallybio Corporation Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo Therapeutics | 146 | Business Wire | EAST BERLIN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced that it will effect a one-for-two reverse stock split of its issued and outstanding common stock in connection... ► Artikel lesen | |
| 04.11. | Rallybio-Aktionäre stimmen Fusion mit Avenzo und Sonderausschüttung zu | 1 | Investing.com Deutsch | ||
| 04.11. | Rallybio Corp - 8-K, Current Report | - | SEC Filings | ||
| 27.10. | Rallybio Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 26.10. | Rallybio kündigt Sonderausschüttung im Zuge der Fusion mit Avenzo an | 2 | Investing.com Deutsch | ||
| 26.10. | Rallybio Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 14.10. | Rallybio Corp - S-4/A, Registration of securities, business combinations | 2 | SEC Filings | ||
| 03.10. | Rallybio Corp - S-4/A, Registration of securities, business combinations | - | SEC Filings | ||
| 10.09. | Avenzo Therapeutics, Inc.: Avenzo Therapeutics to Present Preliminary Phase 1 Study Results of AVZO-1418, a Potentially Differentiated EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th EORTC-NCI-AACR Symposium | 413 | Business Wire | Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced the acceptance of an abstract for poster presentation... ► Artikel lesen | |
| 09.09. | Rallybio Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 26.08. | Rallybio Corp - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 06.08. | Rallybio Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 15.07. | Rallybio Corp - S-4, Registration of securities, business combinations | 2 | SEC Filings | ||
| 14.07. | XFRA NEW INSTRUMENTS AVAILABLE ON 14.07.2026 | 637 | Xetra Newsboard | The following instruments on XETRA do have their first trading 14.07.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.07.2026
Aktien
1 IT0005720005 ETI S.p.A.
2 SGXE42278403... ► Artikel lesen | |
| 01.06. | RallyBio tries again for reverse merger, this time with Avenzo | 2 | BioPharma Dive | ||
| 01.06. | Rallybio swerves past Candid pothole to land deal with cancer drug developer Avenzo | 2 | FierceBiotech |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 73,40 | -1,08 % | BioNTech Aktie: Wehe, diese Marken halten nicht... | Dreimal hat die BioNTech Aktie seit Ende Oktober die Zone um 85 Dollar getestet, dreimal hat sie gehalten. Am Donnerstag war es wieder so weit, und diesmal schloss der Kurs mitten in der Kernzone. Seit... ► Artikel lesen | |
| AMGEN | 400,55 | +0,16 % | Dividendenbekanntmachungen (20.11.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0683 EUR AGNT INC US30212W1009 0,05 USD 0,0455 EUR AMGEN INC US0311621009 2... ► Artikel lesen | |
| VALNEVA | 2,356 | -2,52 % | Valneva: Positive Shigella-Daten - was jetzt für die Aktie zählt | ||
| NOVAVAX | 7,030 | -0,14 % | Novavax: Prognose erhöht - worauf es jetzt ankommt | ||
| BIOGEN | 227,55 | +1,02 % | 10,7 Billionen Dollar (!) Schaden: Lilly, Biogen, Jazz Pharmaceuticals und NeuroThera greifen in diesem Markt an! | ||
| PALATIN TECHNOLOGIES | 4,990 | +1,22 % | Palatin targets phase I start in first half of calendar 2027 for lead MC4R lipidated peptide | ||
| VIVOSIM LABS | 0,279 | -4,46 % | VivoSim Labs (VIVS) Stock Jumps 21% After Hours: What's Driving the Move | ||
| OCUGEN | 0,724 | +8,38 % | Ocugen macht Lizenzdeal mit Celairis: Warum die Marke jetzt zählt | ||
| VIKING THERAPEUTICS | 23,150 | -1,70 % | Viking Therapeutics gains amid report of renewed takeover interest | ||
| INTELLIA THERAPEUTICS | 9,200 | +5,87 % | Intellia Therapeutics (NDQ:NTLA): The World's First Commercial CRISPR Franchise Could Be Closer Than Investors Think | ||
| TEMPUS AI | 50,64 | -6,72 % | AstraZeneca Extends Tempus AI Partnership with $200 Million Commitment as Analyst Weighs Multiples | ||
| VIVORYON THERAPEUTICS | 0,634 | -1,25 % | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Ongoing negotiations with different parties towards securing a partnership or financing for the development... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,666 | +0,15 % | BioCryst presents real-world data on ORLADEYO at ACAAI meeting | ||
| NUREXONE BIOLOGIC | 0,287 | -6,51 % | 14 Tage oder 60 Monate Lagerung: Warum Gilead, Mesoblast und NurExone regenerative Therapien unterschiedlich verfügbar machen | ||
| BIOMARIN PHARMACEUTICAL | 55,90 | -0,07 % | 50 Prozent der neuen US-Arzneien waren Orphan Drugs: Warum BioMarin, Vertex und NurExone kleine Märkte anders entwickeln |